In Business 29 Years - Since 1980
THE CURRENT TIME at LC Labs is:
|
|
||||||
In Business 29 Years - Since 1980 |
THE CURRENT TIME at LC Labs is: |
|||||
[17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin Hydrochloride] [Alvespimycin]
|
 |
 |
|
Size |
US $ |
€ |
£ |
¥ |
|
||
|
250 mg |
117 |
91 |
76 |
10200 |
| ||
|
1 g |
365 |
283 |
237 |
31900 |
| ||
|
2 g |
596 |
461 |
386 |
52200 |
| ||
|
5 g |
930 |
720 |
603 |
81400 |
| ||
|
10 g |
1490 |
1154 |
966 |
130400 |
| ||
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
| Compare Prices and Purity — LC Labs vs. Other Suppliers |
|---|
M.W. 653.21
C32H48N4O8•HCl
[150270-08-9]
Warning: Toxic.
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO; soluble up to about 2 mg/mL in water. Disposal: A
Find and View a Certificate of Analysis for this product
View the MSDS for this product
Synthetic derivative of geldanamycin, Cat. No. G-4500, and water-soluble analog of 17-AAG, Cat. No. A-6880, demonstrating stability and low in vivo toxicity similar to 17-AAG, but undergoes limited metabolism compared to 17-AAG. Egorin, M.J., et al. "Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats." Cancer Chemother. Pharmacol. 49: 7-19 (2002).
Binds specifically to heat shock protein Hsp90 in a manner similar to geldanamycin. Tian, Z.Q., et al. "Synthesis and biological activities of novel 17-aminogeldanamycin derivatives." Bioorg. Med. Chem. 12: 5317-5329 (2004).
Inhibits angiogenesis. Kaur, G, et al. "Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator." Clin. Cancer Res. 10: 4813-4821 (2004).
Enhances the radiation-induced cell cycle arrest of human solid tumor cell lines both in vitro and in vivo. Bull, E.E., et al. "Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin." Clin. Cancer Res. 10: 8077-8084 (2004).
Exhibits potent anti-tumor activity against MDA-MB-231 breast carcinoma cells and HL60-TB leukemia cells both of which are relatively insensitive to 17-AAG. Hollingshead, M., et al. "In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative." Cancer Chemother. Pharmacol. 56: 115-125 (2005).
Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
© 1990-2010 LC Laboratories All rights reserved.
